Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772636 | 0.92 | CD44 (0.54) | CD44MAPTALDH1A1TSHRMEN1 | |
| Hydrochloric Acid SCHEMBL28465623 | 0.91 | CD44 (0.52) | CD44MAPTALDH1A1TSHRMEN1 | |
| SCHEMBL9515068 | 0.85 | ALDH1A1 (0.52) | CD44MAPTALDH1A1TSHRMEN1 | |
| SCHEMBL1193334 | 0.84 | ALDH1A1 (0.60) | MAPTALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL30458055 | 0.84 | ALDH1A1 (0.60) | MAPTALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL30578459 | 0.84 | TSHR (0.59) | MAPTALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL348272 | 0.84 | TSHR (0.59) | MAPTALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL772624 | 0.84 | CYP1A2 (0.48) | MAPTALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL11219818 | 0.84 | TSHR (0.59) | MAPTALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL5068830 | 0.82 | PPIA (0.47) | MAPTALDH1A1TSHRTDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111362867-A | Mobile terminal, shell assembly, electrochromic material and preparation method thereof | 宁波祢若电子科技有限公司 | 2020-07-03 | — | — | CN | claimed |
| JP-56169651-A | — | — | None | — | — | JP | disclosed |
| CN-111362867-B | Mobile terminal, shell assembly, electrochromic material and preparation method thereof | 宁波祢若电子科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-111362867-A | Mobile terminal, shell assembly, electrochromic material and preparation method thereof | 宁波祢若电子科技有限公司 | 2020-07-03 | — | — | CN | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| JP-S56169651-A | PREPARATION OF 4-CHLORO-6-NITRO-M-TOLUIDINE | NIPPON KAYAKU CO LTD | 1981-12-26 | — | — | JP | disclosed |
| US-4009994-A | Process and product of optical brightening with quaternized benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1977-03-01 | — | — | US | disclosed |
| US-3940417-A | Quaternised benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
| US-3931215-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | CD44 825/4885MAPT 2336/4885ALDH1A1 1909/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | CD44 825/4885MAPT 2336/4885ALDH1A1 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.